NASDAQ:IMNM Immunome Q2 2025 Earnings Report $9.00 -0.21 (-2.28%) Closing price 04:00 PM EasternExtended Trading$8.99 -0.01 (-0.06%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Immunome EPS ResultsActual EPS-$0.50Consensus EPS -$0.52Beat/MissBeat by +$0.02One Year Ago EPSN/AImmunome Revenue ResultsActual Revenue$4.02 millionExpected Revenue$1.03 millionBeat/MissBeat by +$2.99 millionYoY Revenue GrowthN/AImmunome Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time9:30AM ETUpcoming EarningsImmunome's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunome Earnings HeadlinesImmunome (NASDAQ:IMNM) Earns Buy Rating from Analysts at Craig HallumSeptember 8 at 2:37 AM | americanbankingnews.comCraig-Hallum Initiates Coverage of Immunome (IMNM) with Buy RecommendationSeptember 6, 2025 | msn.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 10 at 2:00 AM | Banyan Hill Publishing (Ad)Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalystsSeptember 5, 2025 | msn.comImmunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’September 5, 2025 | msn.comWhere Immunome Stands With AnalystsSeptember 5, 2025 | benzinga.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles. The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use. Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.Written by Jeffrey Neal JohnsonView Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
